A Case Report of Recurrent Gastric Leiomyosarcoma Effectively Treated with Etoposide-Adriamycin-Cisplatin Therapy

Hisashi Amaike*, Hideaki Kurioka, Kiyokazu Akioka, Mitsuhiro Fujino, Tatsuyuki Yasuda, Tomoji Nishimoto, Eito Ikeda, Fumitaka Muto, Kyouzou Hashimoto, Takao Ohuchi, Kan-ichi Tanaka, Yoshihiro Harada, Genkou Ishimine

Department of Surgery, Kyoto First Redcross Hospital
*Second Department of Surgery, Kyoto Prefectural University of Medicine

A 65-year-old man came to our hospital with the complaints of pain in the left upper abdomen and an abdominal tumor. After admission, he was diagnosed as having a gastric leiomyosarcoma and a pancreato-total gastrectomy with lymphnode dissection was performed on June 29, 1988. However, a poor defined mass was pointed out in the left abdominal wall in October, 1988, and he was treated with two cycles of EAP (adriamycin 20 mg X2, iv: cis-platin 50 mg X2, div: Etoposide 100 mg X3, div). The response was remarkable, and the effect was judged as complete response by palpation and computed tomography. Now, he is leading a good life without recurrence. EAP therapy is a strong combination chemotherapy with which a high percentage of patients with inoperable advanced gastric cancer achieve complete or partial response. We applied this chemotherapy to the treatment of gastric leiomyosarcoma and obtained a good response. In general, it is rare that gastric leiomyosarcoma shows a good response to chemotherapy, so we report our case with the expectation of further examination. This therapy was accompanied by side effects such as severbone marrow suppression, nausea, vomiting and depilation, but these side effects were all reversible.

Key words
gastric leiomyosarcoma, Etoposid-Adriamycin-Cisplatin therapy

Reprint requests
Hisashi Amaike Seconds Department of Surgery, Kyoto Prefectural University of Medicine
465 Kajii-machi, Kawaramachi-Hirokouji Agaru Kamigyo-ku, Kyoto, 602 JAPAN

Accepted
March 13, 1991

To read the PDF file you will need Abobe Reader installed on your computer.